Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Production and Clinical Evaluation of Norwalk GI.1 Virus Lot 001-09NV in Norovirus Vaccine Development.

Mateo R, Lindesmith LC, Garg SJ, Gottlieb K, Lin K, Said S, Leon JS, Sims AC, Weber DJ, Baric RS, Tucker SN, Taylor DN.

J Infect Dis. 2019 Oct 20. pii: jiz540. doi: 10.1093/infdis/jiz540. [Epub ahead of print]

PMID:
31628848
2.

Human Norovirus Histo-Blood Group Antigen (HBGA) Binding Sites Mediate the Virus Specific Interactions with Lettuce Carbohydrates.

Esseili MA, Gao X, Boley P, Hou Y, Saif LJ, Brewer-Jensen P, Lindesmith LC, Baric RS, Atmar RL, Wang Q.

Viruses. 2019 Sep 8;11(9). pii: E833. doi: 10.3390/v11090833.

3.

Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination.

Lindesmith LC, McDaniel JR, Changela A, Verardi R, Kerr SA, Costantini V, Brewer-Jensen PD, Mallory ML, Voss WN, Boutz DR, Blazeck JJ, Ippolito GC, Vinje J, Kwong PD, Georgiou G, Baric RS.

Immunity. 2019 Jun 18;50(6):1530-1541.e8. doi: 10.1016/j.immuni.2019.05.007.

4.

GII.4 Human Norovirus: Surveying the Antigenic Landscape.

Mallory ML, Lindesmith LC, Graham RL, Baric RS.

Viruses. 2019 Feb 20;11(2). pii: E177. doi: 10.3390/v11020177. Review.

5.

Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands.

Lindesmith LC, Brewer-Jensen PD, Mallory ML, Yount B, Collins MH, Debbink K, Graham RL, Baric RS.

J Virol. 2019 Jan 4;93(2). pii: e01813-18. doi: 10.1128/JVI.01813-18. Print 2019 Jan 15.

6.

Vaccination-induced herd immunity: Successes and challenges.

Mallory ML, Lindesmith LC, Baric RS.

J Allergy Clin Immunol. 2018 Jul;142(1):64-66. doi: 10.1016/j.jaci.2018.05.007. Epub 2018 May 24. No abstract available.

7.

Bat Caliciviruses and Human Noroviruses Are Antigenically Similar and Have Overlapping Histo-Blood Group Antigen Binding Profiles.

Kocher JF, Lindesmith LC, Debbink K, Beall A, Mallory ML, Yount BL, Graham RL, Huynh J, Gates JE, Donaldson EF, Baric RS.

mBio. 2018 May 22;9(3). pii: e00869-18. doi: 10.1128/mBio.00869-18.

8.

Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.

Agnihothram S, Menachery VD, Yount BL Jr.,, Lindesmith LC, Scobey T, Whitmore A, Schäfer A, Heise MT, Baric RS.

J Virol. 2018 May 14;92(11). pii: e00027-18. doi: 10.1128/JVI.00027-18. Print 2018 Jun 1.

9.

Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion.

Lindesmith LC, Mallory ML, Debbink K, Donaldson EF, Brewer-Jensen PD, Swann EW, Sheahan TP, Graham RL, Beltramello M, Corti D, Lanzavecchia A, Baric RS.

mSphere. 2018 Feb 7;3(1). pii: e00518-17. doi: 10.1128/mSphere.00518-17. eCollection 2018 Jan-Feb.

10.

Antigenic Characterization of a Novel Recombinant GII.P16-GII.4 Sydney Norovirus Strain With Minor Sequence Variation Leading to Antibody Escape.

Lindesmith LC, Brewer-Jensen PD, Mallory ML, Debbink K, Swann EW, Vinjé J, Baric RS.

J Infect Dis. 2018 Mar 13;217(7):1145-1152. doi: 10.1093/infdis/jix651.

11.

Emergence of Novel Human Norovirus GII.17 Strains Correlates With Changes in Blockade Antibody Epitopes.

Lindesmith LC, Kocher JF, Donaldson EF, Debbink K, Mallory ML, Swann EW, Brewer-Jensen PD, Baric RS.

J Infect Dis. 2017 Dec 5;216(10):1227-1234. doi: 10.1093/infdis/jix385.

12.

Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.

Lindesmith LC, Mallory ML, Jones TA, Richardson C, Goodwin RR, Baehner F, Mendelman PM, Bargatze RF, Baric RS.

J Infect Dis. 2017 Mar 15;215(6):984-991. doi: 10.1093/infdis/jix045.

13.

Resolution of diarrhea in an immunocompromised patient with chronic norovirus gastroenteritis correlates with constitution of specific antibody blockade titer.

Knoll BM, Lindesmith LC, Yount BL, Baric RS, Marty FM.

Infection. 2016 Aug;44(4):551-4. doi: 10.1007/s15010-016-0875-1. Epub 2016 Jan 29.

PMID:
26825307
14.

Serum Immunoglobulin A Cross-Strain Blockade of Human Noroviruses.

Lindesmith LC, Beltramello M, Swanstrom J, Jones TA, Corti D, Lanzavecchia A, Baric RS.

Open Forum Infect Dis. 2015 Jul 1;2(3):ofv084. doi: 10.1093/ofid/ofv084. eCollection 2015 Sep.

15.

Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.

Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, Richardson C, Goodwin RR, Baehner F, Mendelman PM, Bargatze RF, Baric RS.

PLoS Med. 2015 Mar 24;12(3):e1001807. doi: 10.1371/journal.pmed.1001807. eCollection 2015 Mar.

16.

Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope.

Lindesmith LC, Donaldson EF, Beltramello M, Pintus S, Corti D, Swanstrom J, Debbink K, Jones TA, Lanzavecchia A, Baric RS.

J Virol. 2014 Aug;88(16):8826-42. doi: 10.1128/JVI.01192-14. Epub 2014 May 28.

17.

Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.

Debbink K, Lindesmith LC, Donaldson EF, Swanstrom J, Baric RS.

J Virol. 2014 Jul;88(13):7256-66. doi: 10.1128/JVI.00785-14. Epub 2014 Apr 16.

18.

Within-host evolution results in antigenically distinct GII.4 noroviruses.

Debbink K, Lindesmith LC, Ferris MT, Swanstrom J, Beltramello M, Corti D, Lanzavecchia A, Baric RS.

J Virol. 2014 Jul;88(13):7244-55. doi: 10.1128/JVI.00203-14. Epub 2014 Mar 19.

19.

The state of norovirus vaccines.

Debbink K, Lindesmith LC, Baric RS.

Clin Infect Dis. 2014 Jun;58(12):1746-52. doi: 10.1093/cid/ciu120. Epub 2014 Feb 27.

20.

Human norovirus detection and production, quantification, and storage of virus-like particles.

Debbink K, Costantini V, Swanstrom J, Agnihothram S, Vinjé J, Baric R, Lindesmith L.

Curr Protoc Microbiol. 2013 Nov 5;31:15K.1.1-15K.1.45. doi: 10.1002/9780471729259.mc15k01s31.

21.

Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects.

Swanstrom J, Lindesmith LC, Donaldson EF, Yount B, Baric RS.

J Virol. 2014 Jan;88(2):829-37. doi: 10.1128/JVI.02793-13. Epub 2013 Oct 30.

22.

Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity.

Debbink K, Lindesmith LC, Donaldson EF, Costantini V, Beltramello M, Corti D, Swanstrom J, Lanzavecchia A, Vinjé J, Baric RS.

J Infect Dis. 2013 Dec 1;208(11):1877-87. doi: 10.1093/infdis/jit370. Epub 2013 Aug 1.

23.

Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes.

Lindesmith LC, Costantini V, Swanstrom J, Debbink K, Donaldson EF, Vinjé J, Baric RS.

J Virol. 2013 Mar;87(5):2803-13. doi: 10.1128/JVI.03106-12. Epub 2012 Dec 26.

24.

Norovirus immunity and the great escape.

Debbink K, Lindesmith LC, Donaldson EF, Baric RS.

PLoS Pathog. 2012;8(10):e1002921. doi: 10.1371/journal.ppat.1002921. Epub 2012 Oct 18. No abstract available.

25.

Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.

Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric RS.

PLoS Pathog. 2012;8(5):e1002705. doi: 10.1371/journal.ppat.1002705. Epub 2012 May 17.

26.

Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity.

Debbink K, Donaldson EF, Lindesmith LC, Baric RS.

J Virol. 2012 Jan;86(2):1214-26. doi: 10.1128/JVI.06189-11. Epub 2011 Nov 16.

27.

Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002.

Lindesmith LC, Debbink K, Swanstrom J, Vinjé J, Costantini V, Baric RS, Donaldson EF.

J Virol. 2012 Jan;86(2):873-83. doi: 10.1128/JVI.06200-11. Epub 2011 Nov 16.

28.

Norovirus infectivity in humans and persistence in water.

Seitz SR, Leon JS, Schwab KJ, Lyon GM, Dowd M, McDaniels M, Abdulhafid G, Fernandez ML, Lindesmith LC, Baric RS, Moe CL.

Appl Environ Microbiol. 2011 Oct;77(19):6884-8. doi: 10.1128/AEM.05806-11. Epub 2011 Aug 19.

29.

Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010.

Takanashi S, Wang Q, Chen N, Shen Q, Jung K, Zhang Z, Yokoyama M, Lindesmith LC, Baric RS, Saif LJ.

J Clin Microbiol. 2011 Sep;49(9):3234-44. doi: 10.1128/JCM.00305-11. Epub 2011 Jul 13.

30.

Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens.

Tian P, Yang D, Jiang X, Zhong W, Cannon JL, Burkhardt W 3rd, Woods JW, Hartman G, Lindesmith L, Baric RS, Mandrell R.

J Appl Microbiol. 2010 Nov;109(5):1753-62. doi: 10.1111/j.1365-2672.2010.04812.x. Epub 2010 Aug 2.

31.

Norovirus GII.4 strain antigenic variation.

Lindesmith LC, Donaldson EF, Baric RS.

J Virol. 2011 Jan;85(1):231-42. doi: 10.1128/JVI.01364-10. Epub 2010 Oct 27.

32.

Identification of cross-reactive norovirus CD4+ T cell epitopes.

LoBue AD, Lindesmith LC, Baric RS.

J Virol. 2010 Sep;84(17):8530-8. doi: 10.1128/JVI.00727-10. Epub 2010 Jun 23.

33.

Viral shape-shifting: norovirus evasion of the human immune system.

Donaldson EF, Lindesmith LC, Lobue AD, Baric RS.

Nat Rev Microbiol. 2010 Mar;8(3):231-41. doi: 10.1038/nrmicro2296. Epub 2010 Feb 2. Review.

PMID:
20125087
34.

Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, Johnston RE, Weber DJ, Baric RS.

J Virol. 2010 Feb;84(4):1800-15. doi: 10.1128/JVI.02179-09. Epub 2009 Dec 9.

35.

Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.

Cannon JL, Lindesmith LC, Donaldson EF, Saxe L, Baric RS, Vinjé J.

J Virol. 2009 Jun;83(11):5363-74. doi: 10.1128/JVI.02518-08. Epub 2009 Mar 18.

36.

Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS.

J Virol. 2009 Apr;83(7):3212-27. doi: 10.1128/JVI.01650-08. Epub 2009 Jan 28.

37.

Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations.

Donaldson EF, Lindesmith LC, Lobue AD, Baric RS.

Immunol Rev. 2008 Oct;225:190-211. doi: 10.1111/j.1600-065X.2008.00680.x. Review.

PMID:
18837783
38.

Norwalk virus: how infectious is it?

Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, Le Pendu J, Calderon RL.

J Med Virol. 2008 Aug;80(8):1468-76. doi: 10.1002/jmv.21237.

PMID:
18551613
39.

Mechanisms of GII.4 norovirus persistence in human populations.

Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS.

PLoS Med. 2008 Feb;5(2):e31. doi: 10.1371/journal.pmed.0050031.

40.

Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome.

Yount B, Roberts RS, Lindesmith L, Baric RS.

Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12546-51. Epub 2006 Aug 4.

41.

Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains.

LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, Moe CL, Baric RS.

Vaccine. 2006 Jun 12;24(24):5220-34. Epub 2006 Apr 18.

PMID:
16650512
42.

Cellular and humoral immunity following Snow Mountain virus challenge.

Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS.

J Virol. 2005 Mar;79(5):2900-9.

43.
44.

Is my lung function really that good? Flow-type spirometer problems that elevate test results.

Townsend MC, Hankinson JL, Lindesmith LA, Slivka WA, Stiver G, Ayres GT.

Chest. 2004 May;125(5):1902-9.

PMID:
15136405
45.

Human susceptibility and resistance to Norwalk virus infection.

Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R.

Nat Med. 2003 May;9(5):548-53. Epub 2003 Apr 14.

PMID:
12692541
47.

Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons.

Baric RS, Yount B, Lindesmith L, Harrington PR, Greene SR, Tseng FC, Davis N, Johnston RE, Klapper DG, Moe CL.

J Virol. 2002 Mar;76(6):3023-30.

48.

Identification of kinesin-associated proteins.

Lindesmith LC, Kumar J, Sheetz MP.

Methods Mol Biol. 2001;164:205-12. Review. No abstract available.

PMID:
11217608
49.

Phosphotransferases associated with the regulation of kinesin motor activity.

Lindesmith L, McIlvain JM Jr, Argon Y, Sheetz MP.

J Biol Chem. 1997 Sep 5;272(36):22929-33.

50.

166Holmium-containing glass for internal radiotherapy of tumors.

Brown RF, Lindesmith LC, Day DE.

Int J Rad Appl Instrum B. 1991;18(7):783-90.

PMID:
1787088

Supplemental Content

Loading ...
Support Center